Antimalarial Agent

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes the use of specific chemical compounds, particularly N,N'-bis(3,5-diacetylphenyl)decanediamide-tetrakis(amidinohydrazone) and its variants, as a treatment or preventive medication for malaria. These compounds have shown effectiveness against various malaria parasites, including those resistant to common anti-malarial drugs, and also exhibit low toxicity and anti-inflammatory effects.

Use CasesContent extracted from patent full text and abstract with AI.

• Therapeutic treatment of malaria in humans, especially cases caused by drug-resistant Plasmodium species (e.g., Plasmodium falciparum).
• Prophylactic (preventive) administration for travelers or populations at risk of malaria infection.
• Treatment of cerebral malaria, a severe form of the disease, to prevent brain complications.
• Use in veterinary medicine for prevention and treatment of malaria-like diseases in animals such as rodents.
• Potential adjunct therapy in cases of malaria and HIV co-infection due to observed antiviral effects.

BenefitsContent extracted from patent full text and abstract with AI.

• Demonstrates effectiveness against Plasmodium strains resistant to established drugs like chloroquine, mefloquine, and pyrimethamine.
• Exhibits low or negligible toxicity, allowing for safer, prolonged, or preventive use.
• Reduces inflammation and may prevent organ damage caused by malaria-induced immune responses, particularly lowering TNF-alpha levels that are linked to severe malaria complications.
• Can be administered via multiple routes (oral, intravenous), providing flexibility in treatment settings.
• Reduces the parasite load in both laboratory cultures and animal models, supporting its efficacy.
• Potentially shortens the pre-treatment and total duration required for effective prophylaxis compared to existing drugs.
• Shows some antiviral activity (e.g., against HIV), offering extra benefit where malaria and viral infections coexist.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to the use of compounds of general formula (I), particularly N,N'-bis(3,5-diacetylphenyl)decanediamide-tetrakis(amidinohydrazone) and/or the enantiomers, diastereomers, and pharmaceutically acceptable salts thereof for producing a medicament utilized for the treatment of malaria.